Healthy
Conditions
Brief summary
This is a Phase 1 study designed to explore the safety, tolerability and pharmacokinetics of K-755 following oral administration to healthy male and female volunteers.
Interventions
DRUGK-755 Part A (SAD)
Single ascending dose (SAD). There will be 7 cohorts in the Part A. Three quarters of subjects will receive K-755 tablet orally in a double-blind fashion.
DRUGPlacebo Part A (SAD)
Single ascending dose (SAD). In Part A, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
DRUGK-755 Part B (MAD)
Multiple ascending dose (MAD). There will be 4 cohorts in the Part B. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
DRUGPlacebo Part B (MAD)
Multiple ascending dose (MAD). In Part B, one quarter of subjects will receive placebo tablet orally in a double-blind fashion.
DRUGK-755 Part C (FE)
Food effect (FE). All subjects in Part C will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
DRUGK-755 Part D (FE)
Food effect (FE). All subjects in Part D will receive K-755 oral tablet both under fed and fasted condition in a open-label, crossover fashion.
DRUGK-755 Part E (MAD)
Multiple ascending dose (MAD). There will be 2 cohorts in the Part E. Three quarters of subjects will receive K-755 oral tablet in a double-blind fashion.
DRUGPlacebo Part E (MAD)
Multiple ascending dose (MAD). In the Part E. One quarter of subjects will receive placebo tablet orally in a double-blind fashion.
Sponsors
Kowa Company, Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Masking description
Masking for Part A (SAD) , Part B (MAD), Part E (MAD) open for Part C (FE) and Part D (FE)
Intervention model description
Sequential Assignment/Crossover (for food effect)
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Able to comprehend and willing to sign an ICF and to abide by the study restrictions. 2. Males or females, of any race, between 18 and 45 years of age. 3. Body mass index (BMI) between 18.0 and 28.0 kg/m2. 4. Hematology, clinical chemistry, and urinalysis test results within the reference ranges or showing no clinically relevant deviations, as judged by the Investigator. 5. No clinically significant abnormalities on the basis of medical history, physical examination findings, and vital signs. 6. All females must have a negative serum pregnancy test. 7. Able and willing to comply with the protocol and study procedures.
Exclusion criteria
1. Female subject who are pregnant or breastfeeding. 2. Subject with presence of active or recurring clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease requiring medical treatment. 3. Subject with any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of K-755. 4. Subject with presence of an active malignancy or within the past 5 years a malignancy of any type, other than basal cell carcinoma of the skin. 5. Subject has a history of type 1 hypersensitivity to any medication and/or clinically relevant food allergies. 6. Subject has a history of drug addiction. 7. Subject has a positive screen for drugs of abuse, cotinine or alcohol. 8. Subject has a history of regular alcohol consumption within 6 months of the study. 9. Subject has smoked tobacco within 6 months prior to Check-in, or has used non-inhaled tobacco- or nicotine-containing products within 3 months prior to Check-in. 10. Subject has used prescription or over-the-counter medications, dietary/nutritional supplements (except paracetamol or vitamin supplements) 11. Subject has used steroid medications (oral, inhaled, parenteral, or topical) within 30 days or 5 half-lives (whichever is longer) before study drug administration. 12. Subject has participated in an investigational drug study within 30 days or 5 half-lives (whichever is longer) before study drug administration. 13. Subject has a positive screen for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 and 2 antigens/antibodies. 14. Subject has had a clinically significant acute illness within 4 weeks or other illness within 5 days before the first study drug administration. 15. Subject or a family member of the subject is a member of the professional or ancillary personnel working at the investigative site involved in the study. 16. Not suitable for entry into the study in the opinion of the Investigator. 17. Receipt of blood products within 2 months prior to Check-in.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part A, B, C, D and E: Incidence and severity of Adverse Events | Up to 28 days after last administration | A treatment-emergent adverse events (TEAE) will be summarized by treatment and overall, and summarized for each treatment by severity and relationship to study drug. All TEAEs leading to withdrawal, or SAEs, will be summarized. |
| Part A, B, C, D and E: Number of subjects with clinical laboratory test abnormalities | Up to 28 days after last administration | The clinical laboratory will include hematology (hematocrit, hemoglobin, mean cell hemoglobin, mean cell hemoglobin concentration, mean cell volume, platelet count, red blood cell count, white blood cell count), clinical chemistry (alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, calcium, chloride, cholesterol, creatinine, creatine phosphokinase, direct bilirubin, estimated glomerular filtration rate, gamma glutamyl transferase, glucose. inorganic phosphate, iron, lactate dehydrogenase, phosphorus, potassium, sodium, total bilirubin, total CO2, total protein, triglyceride, urea, uric acid), and urinalysis (bilirubin, blood, color and appearance, glucose, ketones, leukocyte esterase, nitrite, pH, protein, specific gravity, urobilinogen, microscopic examination, electrolytes). Abnormality will be determined by the investigator. |
| Part A, B, C, D and E: Number of subjects with vital signs abnormalities | Up to 28 days after last administration | The vital sign will include blood pressure (mmHg), pulse rate (bpm), respiratory rate (breaths/min), and body temperature (degree Celsius). Abnormality will be determined by the investigator. |
| Part A, B, C, D and E: Number of subjects with clinically significant change in body weight | Up to 28 days after last administration | Change in body weight (kg) at baseline and post dose will be measured. Clinical significance will be determined by the investigator. |
| Part A, B, C, D and E: Number of subjects with abnormal findings in physical examinations | Up to 28 days after last administration | The physical examination will typically include general appearance, head and neck, eyes, ear, nose and throat, lymph nodes, thyroid, cardiovascular, respiratory, abdomen, nervous, skin, musculoskeletal, peripheral vascular and extremities and be performed at Investigator's discretion based on reported symptoms. Abnormality will be determined by the investigator. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part A: Tmax of K-755 | Up to 28 days after single administration | Time of the observed maximum plasma concentration |
| Part A: t1/2 of K-755 | Up to 28 days after single administration | Terminal plasma elimination half-life |
| Part B: AUC0-τ of K-755 | Up to 28 days after repeated administration | AUC over the dosing interval |
| Part B: Cmax of K-755 | Up to 28 days after repeated administration | Maximum plasma concentration |
| Part B: Tmax of K-755 | Up to 28 days after repeated administration | Time of the observed maximum plasma concentration |
| Part B: t1/2 of K-755 | Up to 28 days after repeated administration | Terminal plasma elimination half-life |
| Part C: AUC0-inf of K-755 | Up to 14 days after single administration | Area under the plasma concentration-time curve (AUC) from time zero extrapolated to infinity |
| Part C: AUC0-tlast of K-755 | Up to 14 days after single administration | AUC from time zero to the time of the last measurable concentration |
| Part C: t1/2 of K-755 | Up to 14 days after single administration | Terminal plasma elimination half-life |
| Part C: Cmax of K-755 | Up to 14 days after single administration | Maximum plasma concentration |
| Part D: AUC0-tlast of K-755 | Up to 14 days after single administration | AUC from time zero to the time of the last measurable concentration |
| Part D: Cmax of K-755 | Up to 14 days after single administration | Maximum plasma concentration |
| Part D: Tmax of K-755 | Up to 14 days after single administration | Time of the observed maximum plasma concentration |
| Part D: t1/2 of K-755 | Up to 14 days after single administration | Terminal plasma elimination half-life |
| Part E: AUC0-τ of K-755 | Up to 14 days after single administration | AUC over the dosing interval |
| Part E: Cmax of K-755 | Up to 14 days after single administration | Maximum plasma concentration |
| Part E: Tmax of K-755 | Up to 14 days after single administration | Time of the observed maximum plasma concentration |
| Part E: t1/2 of K-755 | Up to 14 days after single administration | Terminal plasma elimination half-life |
| Part D: AUC0-inf of K-755 | Up to 14 days after single administration | Area under the plasma concentration-time curve (AUC) from time zero extrapolated to infinity |
| Part C: Tmax of K-755 | Up to 14 days after single administration | Time of the observed maximum plasma concentration |
| Part A: AUC0-inf of K-755 | Up to 28 days after single administration | Area under the plasma concentration-time curve (AUC) from time zero extrapolated to infinity |
| Part A: AUC0-tlast of K-755 | Up to 28 days after single administration | AUC from time zero to the time of the last measurable concentration |
| Part A: Cmax of K-755 | Up to 28 days after single administration | Maximum plasma concentration |
Countries
Australia
Outcome results
None listed